LONDON and NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage gene therapy company, today announced that on October 2nd, 2018, it expanded its leadership team with the appointment of Katherine Breedis as chief financial officer. Prior to joining MeiraGTx, Ms. Breedis was a managing director, equity research, and senior analyst for biotechnology and major pharmaceuticals with Stifel Nicolaus & Company.
“Katherine is an experienced professional with more than 30 years in the financial and pharmaceutical industries, where she developed strong relationships with the financial community,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “We are pleased to have Katherine join our team and are confident that her leadership, expertise and insights will help us grow the company as we advance our broad portfolio of gene therapies.”
Prior to joining Stifel Nicolaus & Company in 2015, Ms. Breedis worked for several years in the pharmaceuticals industry. At Pfizer Inc., she served as senior director, corporate strategy, providing guidance to the company’s executive leadership team and board of directors on mergers and acquisitions, business development, competitive landscape assessments and long-range corporate strategic planning. Before that, she was senior director, global external research and development, at Eli Lilly & Company. Earlier in her career, she held a number of positions in the financial industry, including first vice president/healthcare equity analyst at Schroder Investment Management North America; principal and founder of Teewinot Capital Investors, LLC, where she focused on equity investments within the specialty/major pharmaceuticals, biotechnology and medical technology sectors; and vice president, global investment research, and senior analyst, specialty pharmaceuticals at Goldman Sachs & Co. Before that, she held positions at Citigroup Asset Management, General Electric Capital Corporation, Creditanstalt-Bankverein, Dillon, Read & Co. and Citibank, N.A.
“I’ve followed and analyzed dozens of biopharma companies as they have developed innovative therapies and brought them through clinical development and regulatory approval to commercialization. I believe MeiraGTx is well-positioned to be a leader in gene therapy and am especially impressed by MeiraGTx’s expert management team, broad, potentially best-in-class pipeline and high-quality, internal cGMP manufacturing capabilities,” said Ms. Breedis. “I’m excited to be joining the team and look forward to contributing my financial expertise to help MeiraGTx progress toward its goal of delivering cures to patients living with devastating diseases.”
Ms. Breedis holds a B.A. in economics and art history from Wheaton College. She is a chartered financial analyst (CFA) and a chartered market technician (CMT). She also serves as an advisor to the Rockefeller University Robertson Therapeutic Development Fund.
MeiraGTx (NASDAQ:MGTX) is a vertically integrated, clinical stage gene therapy company with four ongoing clinical programs and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, severe forms of xerostomia and neurodegenerative diseases. Though initially focusing on the eye, salivary gland and central nervous system, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.
For more information, please visit www.meiragtx.com.